SCHEMBL880415

SCHEMBL880415

CC(C)(C)c1cc(/C=N/Nc2nc3ccccc3[nH]2)cc(C(C)(C)C)c1O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 19/20 0.69
▸ GAA P10253 18/20 0.69
▸ KDM4E B2RXH2 5/20 0.69
▸ TDP1 Q9NUW8 5/20 0.69
▸ HTT P42858 5/20 0.69
▸ NPSR1 Q6W5P4 3/20 0.69
▸ TP53 P04637 2/20 0.69
▸ LMNA P02545 2/20 0.69
▸ RAB9A P51151 13/20 0.63
▸ NPC1 O15118 12/20 0.63
▸ KMT2A Q03164 11/20 0.63
▸ MEN1 O00255 10/20 0.63
▸ SMN1; SMN2 Q16637 6/20 0.63
▸ HPGD P15428 4/20 0.60
▸ ALDH1A1 P00352 3/20 0.60
▸ POLB P06746 2/20 0.60
▸ GFER P55789 2/20 0.60
▸ CYP1A2 P05177 1/20 0.60
▸ CYP2D6 P10635 1/20 0.60
▸ CYP2C9 P11712 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10280286 0.78 MAPT (1.00) MAPTGAAKDM4ETDP1HTT
SCHEMBL15359675 0.75 MAPT (0.76) MAPTGAAKDM4ETDP1HTT
SCHEMBL10280287 0.75 MAPT (0.76) MAPTGAAKDM4ETDP1HTT
SCHEMBL12682633 0.75 MAPT (1.00) MAPTGAAKDM4ETDP1HTT
SCHEMBL880223 0.75 GAA (1.00) MAPTGAAKDM4ETDP1HTT
SCHEMBL23906527 0.74 MAPT (0.79) MAPTGAAKDM4ETDP1HTT
SCHEMBL880461 0.73 MAPT (0.76) MAPTGAAKDM4ETDP1HTT
SCHEMBL10280285 0.73 MAPT (0.73) MAPTGAAKDM4ETDP1HTT
SCHEMBL880212 0.73 PLA2G10 (0.72) MAPTGAAKDM4ETDP1HTT
SCHEMBL880195 0.72 GAA (0.75) MAPTGAAKDM4ETDP1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440705-B2 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2013-05-14 — — US disclosed
US-8440705-B2 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2013-05-14 — — US disclosed
EP-2433634-A2 Compounds, compositions and methods of inhibiting a-synuclein toxicity The Whitehead Institute for Biomedical Research (US) 2012-03-28 — — EP disclosed
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2008-10-23 — — US disclosed
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity SNCA, PARK7, HTT MAPT 30/4885GAA 62/4885KDM4E 1289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback